IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients

By Choy B.Y.   Chan T.M.   Li F.K.   Lui S.L.   Lo W.K.   Yip T.   Tse K.C.   Lai K.N.  

Transplantation Proceedings, Vol. 35, Iss. 1, 2003-02 ,pp. : 195-195

Elsevier

Access to resources Recommend Favorite

Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients

By Sterkers G.   Baudouin V.   Ansart-Pirenne H.   Maisin A.   Niaudet P.   Cochat P.   Loirat C.  

Transplantation Proceedings, Vol. 32, Iss. 8, 2000-12 ,pp. : 2757-2759

Elsevier

Access to resources Recommend Favorite

Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction

By Nampoory M.R.N.   Abdulhalim M.   Johny K.V.   Al-Jawad Donia F.A.   Nair M.P.   Said T.   Homoud H.   Samhan M.   Al-Mousawi M.  

Transplantation Proceedings, Vol. 34, Iss. 7, 2002-11 ,pp. : 2916-2919

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression

By Ciancio G.   Burke G.W.   Suzart K.   Vaidya A.   Roth D.   Kupin W.   Mattiazzi A.   Rosen A.   Esquenazi V.   Miller J.  

Transplantation Proceedings, Vol. 35, Iss. 2, 2003-03 ,pp. : 873-874

Elsevier

Access to resources Recommend Favorite

Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors

By Sanchez-Fructuoso A.I.   Prats D.   Marques M.   Ridao N.   Conesa J.   Garcia Mena M.   Torrente J.   Barrientos A.  

Transplantation Proceedings, Vol. 35, Iss. 5, 2003-08 ,pp. : 1689-1690

Elsevier

Access to resources Recommend Favorite